Ipsen Bioinnovation

Ipsen Bioinnovation (formerly Syntaxin)

In March 2015, Syntaxin has changed its name to Ipsen Bioinnovation.

Ipsen acquired Syntaxin in July 2013 to enhance its leadership in the field of toxins and explore the discovery and development of new innovative compounds for patients with movement disorders. This name change successfully completes the integration process of Syntaxin into Ipsen and consolidates our R&D position in the UK and global toxin presence.   

Ipsen Bioinnovation is a leader in recombinant botulinum toxin technology; this R&D center has an expertise in natural and modified recombinant botulinum toxins, and in targeted secretion inhibitors or retargeted molecules. This name change reinforces Ipsen’s leadership position as we continue to develop a highly differentiated and innovative toxin platform.

Contact :

Units 4-10 The Quadrant
Barton Lane
Oxon OX14 3YS

Tel: +44 (0) 1235 552100
Fax: +44 (0) 1235 552200


Updated on 19 March 2015